Dr. Tse-Wen Chang, President and CEO

Please see Founder.

Dr. Hsing-Mao Art Chu, Vice President of R&D

Dr. Chu obtained his B.Sc. degree from Chang Gung University, M.Sc. degree from National Yang-Ming University, and Ph.D. degree from National Taiwan University. 

He started his postdoctoral research in the Institute of Biological Chemistry, Academia Sinica, and joined Dr. Chang’s laboratory in the Genomics Research Center, Academia Sinica in 2011 to study various antibody engineering methodologies and to work on CemX and anti-CemX antibodies.


He was invited to join Immunwork to lead the research team in 2015. He works as the Vice President of R&D now.

Ms. Ying-Rong Lai, Vice President of Administration & Executive Assistant to Chairman

Ms. Lai obtained her Master degree in Biotechnology Management from National Taiwan University. After graduating from university in 1998, she worked in several fields, including cost control and estimation within the company, participating in biddings of multiple industries, spending several years in the high education system and engaged in trade operation and finally entered the financial system. According to her excellent management experiences in several business sectors, she was invited to work as the financial executive.

From 2004 to 2014, she was a key manager of investment at Taishin International Commercial Bank and at Yuanta Commercial Bank and won a number of service excellence awards. 

In 2014, she was invited by Dr. Tse-Wen Chang to join Immunwork and was responsible for assisting in establishment, administrative and financial affairs of Immunwork. She works as the Vice President of Administration & Executive Assistant to Chairman now.

Dr. Kun-Po Li, Director, Business Development

Dr. Li received B.Sc. and M.Sc. degrees from National Taiwan University and Ph.D. degree in Immunology from University of Cincinnati.

Before joining Immunwork in 2020, Dr. Li worked at the Greater Boston Campus of Sanofi, where he was a project manager, leading translational medicine studies of multiple products in immuno-oncology, autoimmune, and rare diseases therapeutic areas.

Prior to Sanofi, Dr. Li worked at Compass Therapeutics, Inc. to support research of therapeutic antibodies and bi-specific antibodies. In Immunwork, Dr. Li is responsible for external collaboration.

Dr. Pei-Min Chen, Senior Manager, Drug Development and Regulatory Affairs

Dr. Chen received her Ph.D. degree in microbiology from National Taiwan University and had 6 years of industry experience in drug translational development working in CAP-accredited medical laboratories.

Before joining Immunwork in 2021, she was the Director of Preclinical and Clinical Research at United Biomedical, Inc., Asia, responsible for the development of two peptide-based human vaccines (an immunotherapeutic vaccine and a COVID-19 vaccine).

Dr. Chen has ample experience in GLP- and GCLP-compliant studies, pre-IND meetings, and IND applications for first-in-human clinical trials.

Dr. Allen Yueh-Hsiang Yu, Senior Manager, Preclinical Development of Oncology Drugs

Dr. Yu received his B.Sc. and M.Sc. degrees from National Tsing Hus University in 2000 and 2002, and Ph.D. from National Defense Medical University in 2012.

He then started his postdoctoral research in the Genomic Research Center, Academia Sinica, and was responsible for estalishing a single B-cell cloning platform and identifying various antibodies against infectious diseases. 

In 2019, Allen was hired as an associate research fellow in Immunwork and was promoted to a project manager in 2020, a senior manager in 2023, responsible for oncological programs.


Dr. Ya-Shan Chuang, Senior Manager, Medical Affairs

Dr. Chuang obtained a B.Sc. degree in Life Science from National Tsing Hus University and a Ph.D. degree in the field of Biochemistry, Molecular and Cell Biology from Cornell University in the United States.

Before joining Immunwork in 2023, Dr. Chuang served as a project manager at Medigen Vaccine Biologics Corp., where he was responsible for the preclinical study of COVID-19 vaccine development and participated in clinical trials.

Currently, Dr. Chuang is mainly responsible for the planning of clinical trials of various drugs in Immunwork.


Dr. Wendy Mun-Teng Wong, Manager, Preclinical/Clinical Transition of Drug Development

Dr. Wong received her B.Sc. degree in Biomedicine in 2008 and Ph.D. in Biomedicine (Molecular and Cellular Biology) in 2013 from Universiti Sains Malaysia.

She did postdoctoral research on HCV replication pathway at the Institute of Biomedical Sciences, Academia Sinica in 2013-17.

Dr. Wong was recruited as associate research fellow in Immunwork in 2018 and was promoted to a project manager for programs on diabetes, obesity, and fatty liver diseases in 2020.


Dr. Ting Chen, Manager, Strategy of Product Portfolio

Dr. Chen received her B.Sc. degree from National Taiwan Normal University in 2001, M.Sc. degree from National Taiwan University in 2003, and Ph.D. degree from National Tsing Hua University in 2010.

Before joining Immunwork in 2022, she did postdoctoral research on drug development against enterovirus A71 and SARS-CoV-2 at the Institute of Biomedical Sciences, Academia Sinica.

In her current position, Dr. Chen is responsible for communication with government agencies, planning investor awareness matters, and helping product portfolio strategies.

Dr. Jon Wright, Manager, A.I. and Computational Modeling

Dr. Jon received his Ph.D. in Chemistry and Biochemistry from the University of Essex, U.K. in 1996.

Following this he took up a postdoctoral position at the Institute of Biomedical Sciences, Academia Sinica where he researched protein-protein, protein-DNA and protein-small molecule interactions with an emphasis on complex structural modeling, dynamics and design.

During his time at IBMS he operated as both researcher and lab manager until 2022 when he joined Immunwork to take up the position of manager of A.I. and Computational Modeling.